Importantly, these effects are blocked by actin cytoskeleton disrupting agents or the ROCK inhibitor Y-27632, providing additional evidence that actin reorganization, shown to be a prominent event in mAR-stimulated prostate cancer cells [Fig 1A and ref [7,8,41]], and the newly identified Rho/ROCK signaling [17] control testosterone-BSA-induced apoptosis in DU145 cells. The gene discussed is RHO; the disease is prostate carcinoma.